Drug · Small Molecule

Vociprotafib

CI-DRUG-00000642Explore in graph →NCIt C155850 CHEMBL5314427 CIViC Phase 2

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	1	6	—	—	Sep 28, 2018
Malignant Lung Neoplasm	Phase2	Phase 2	0	2	—	—	Dec 30, 2021
Malignant Pancreatic Neoplasm	Phase1	Phase 1	0	1	—	—	Mar 31, 2022

Computedclinicaltrials

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12C1
ARS-1620 + Sotorasib +

Clinical trials

Trials with this intervention (6)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–6 of 6 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05054725	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	completed	Phase 2	47	Revolution Medicines, Inc.INDUSTRY	10	Jan 6, 2026	clinicaltrials
NCT04185883	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	active not recruiting

Molecule

Record

Kind: Small Molecule
Aliases: 2-Pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl-, (6-((2-Amino-3-chloropyridin-4-yl)sulfanyl)-3-((3S,4S)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)- 5-methylpyrazin-2-yl)methanol, PTPN11 Inhibitor RMC-4630, RMC-0694630, RMC 4630, RMC-4630, RMC4630, SAR 442720, SAR-442720, SAR442720, SAR442729, SHP2 Inhibitor RMC-4630, Vociprotafib

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.